Pharmacokinetics study on mesoporous silica-captopril controlled release systems

Digest Journal of Nanomaterials and Biostructures

Volumn 6, Issue 4, 2011, Pages 1619-1630

  Popovici, R F ^a   Alexa, I F ^b   Novac, O ^c   Vrinceanu, N ^b   Popovici, E ^b   Lupusoru, C E ^d   Voicu, V A ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b ALEXANDRU IOAN CUZA UNIVERSITY OF IASI   (Romania)

^c GHEORGHE ASACHI TECHNICAL UNIVERSITY OF IASI   (Romania)

^d GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Captopril; Drug delivery; HPLC; In vivo; Mesoporous silica; Rats

Indexed keywords

RATTUS;

EID: 80054739526     PISSN: None     EISSN: 18423582     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Li Z, Wen L, Shao L, Chen J. J Control Release, 98, 245 (2004).
2. Xu L, Li S, Sunada H, Asian Journal of Pharmaceutical Sciences, 1, 236-245, (2006).
3. Salonen J, Kaukonen AM, Hirvonen J, Lehto VP,.Pharm.Sci, 97(2), 632-653, (2008).
4. Salonen J, Laitinen L, Kaukonen AM, J.Control. Release, 108, 362-374, (2005).
5. Lin X, Qiao S.Z, Yu C.Z., Lu G.Q., Micropor Mesopor Mater, 117, 213-219, (2009).
6. Popovici RF, Mihai CT, Seftel EM, Rotinberg P, Popovici E, Voicu VA, Digest Journal of Nanomaterials and Biostructures, 6, 3, 999-1010 (2011).
7. Vallet-Regi M, J. Intern. Med. 267, 22-43, (2009).
8. Nur AO, Zang JS, International Journal of Pharmaceutics, 66, 139, (2000).
9. Kinnari P, Mäkilä E, Heikkilä T, Salonen J, Hirvonen J, Santos HA, International Journal of
10. Pharmaceutics, doi:10.1016/j.ijpharm (2011).
11. Qu F, Zhu G, Shiying Huang, Li S, Sun J, Daliang Zhang D, Qiu P, Microporous and Mesoporous Materials, 92(1-3), 1-9, (2006).
12. Avdeef A, Absorption and drug development: solubility, permeability, and charge state, Wiley, Hardcover, 312, (2003).
13. Stulzer HK, Rodrigues PO, Cardoso TM, Matos JSR, Silva MRS, Journal of Thermal Analysis and Calorimetry, 91, 1, 323-328, (2008).
14. Lee KJ, Khang A, Delfino JJ, West TG, Chetty D, Monkhouse DC, Yo J, Design and Evaluation of a sustained release gastroretentive dosage form of captopril: A technical note, Drug. Dev. Ind. Pharm., 29, 967, (2003).
15. Khan MA, Sastry SR, Vaithiyalingam SR, Agarwal V, Nazzal S, Reddy IK, Oral Controlled Release Formulation Design and Drug Delivery, Int. J. Pharm., 193, 147 (2000).
16. Chien-Yuan L., Gan-Lin C, Drug Release from Hydroxypropil Cellulose and Polyethylene oxide capsules: In vitro and in vivo Assesment, The Chinese Pharmaceutical Journal, 58, 57-65, (2006).
17. Komai T, Ikeda T, Kawai K, Kameyama E, Shendo H, In vitro study on the metabolic pathway on captopril, J Pharmacobio-Dynam, 4, 677, (1981).
18. Popovici RF, Mihai CT, Seftel EM, Rotinberg P, Popovici E, Voicu VA, Interactions of the mesoporous silica-captopril nanocomposites with some metabolic processes in monkey kidney Vero cells, Digest Journal of Nanomaterials and Biostructures, issue 2, (2011).
19. Hamilton MA, Russo CR, Thurston VR, Trimmed Spearman-Karber Method for Estimating Median Lethal Concentrations in Toxicity Bioassays, Environmental Science & Technology, 11(7), 717, (1977).
20. Popovici RF, Seftel EM, Mihai GD, Popovici E, Voicu V. A., Controlled Drug Delivery System Based on Ordered Mesoporous Silica Matrices of Captopril as Angiotensin-Converting Enzyme Inhibitor Drug, Journal of Pharmaceutical Sciences, 100, 2, (2011).
21. Zhao D, Feng J, Huo Q, Melosh, N, Fredrickson, GH, Chmelka B F, Stucky G D, Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores, Science, 279, 548-552, (1998).
22. Wirongrong T, Mauer LJ, Wongruong S, Sriburi P, Rachtanapun P, Effect of carboxymethyl cellulose concentration on physical properties of biodegradable cassava starch-based films, Chemistry Central Journal, 5,6 (2011).
23. H. van Herck, V. Baumans, C. J. W. M. Brandt, H. A. G. Boere, A. P. M. Hesp, H. A. Van Lith, M. Schurink and A. C. Beynen, Blood sampling from the retro-orbital plexus, the saphenous vein and the tail vein in rats: comparative effects on selected behavioural and blood variables, Laboratory Animals, 35, 131-139, (2001).
24. Kresge CT, Leonowicz M.E., Roth W.J, Vartuli J.K, Beck J.S., A new family of mesoporous molecular sieves, Nature, 359, 710, (1992).
25. McCullen S.B., Vartuli J.C., Kresge C.T., Roth W.J, Beck J.S, Schmitt K.D., Leonowicz M.E., Schlenker J.L., Shih S.S, Lutner J.D., A New Family of Mesoporous Molecular Sieves, Fundamental Materials Research, Part 1, 1-11, (2002).
26. Hamilton MA, Russo CR, Thurston VR, Trimmed Spearman-Karber Method for Estimating Median Lethal Concentrations in Toxicity Bioassays, Environmental Science & Technology, 11, 7, 717, (1977).
27. http://www.ccohs.ca/oshanswers/chemicals/ld50.html.
28. Silion M, Hritcu D, Jaba MI, Tamba B, Ionescu D, Mungiu OC, Popa MI, In vitro and in vivo behavior of ketoprofen intercalated into layered double hydroxides, J.Mater Sci: Mater Med, 21, 3009-3018, (2010).
29. Vavrinkova H, Tutterova M, Stopka P, Divisova J, Kazdova L, Drahota Z, The effect of captopril on nitric oxide formation in ischemic rat heart, Heart Physiol. Res. 50, 481-489, (2001).
30. I.F. Alexa, R.F. Popovici, M. Ignat, E. Popovici, V. A. Voicu, Non-toxic nanocomposite containing captopril intercalated into green inorganic carrier, Digest Journal of Nanomaterials and Biostructures, 6, 3, (2011).